MYST1: A Potential Drug Target for Chromatin Regulation (G84148)

Target Name: KAT8

NCBI ID: G84148

KAT8

MYST1: A Potential Drug Target for Chromatin Regulation

Histone acetyltransferase MYST1 is a enzyme that plays a critical role in the regulation of gene expression and cell signaling. It is a key enzyme in the histone acetylation pathway, which is a process that helps to establish the spatial organization of chromatin and control the distribution of gene expression.MYST1 is highly conserved across various species and has been identified as a potential drug target in various diseases, including cancer.

The histone acetylation pathway is a complex process that involves the recruitment of a variety of enzymes to the chromatin complex. The first step in the pathway is the recruitment of the enzyme MyST1 to the chromatin complex. MyST1 is a nuclear protein that consists of 258 amino acids and has a molecular weight of 31 kDa. It has a distinct N-terminal and C-terminal region, with the N-terminal region containing a conserved N-acetyl group (-NH2) and the C-terminal region containing a conserved G-acetyl group (-COOH).

The function of MyST1 is to add acetyl groups to the histones, which are small proteins that make up the nucleosome, the basic unit of chromatin. The acetyl groups help to establish a positive charge on the chromatin, which can attract other proteins to the complex. This is important for the regulation of gene expression and the maintenance of chromosomal stability.

MYST1 is a key enzyme in the histone acetylation pathway because it is the only enzyme that adds the acetyl groups to the histones. The addition of these groups is critical for the recruitment of other enzymes to the chromatin complex, including the histone methyltransferases that add methyl groups to the histones, which can modulate gene expression.

The histone acetylation pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and response to environmental stress. Mutations in the MYST1 gene have been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the potential benefits of targeting MYST1 as a drug target is its potential to treat a variety of diseases.MYST1 has been shown to be involved in the regulation of many cellular processes, including cell growth, differentiation, and response to environmental stress. This makes it an attractive target for the development of new drugs that can modulate these processes and potentially treat a variety of diseases.

In addition to its potential therapeutic applications, targeting MYST1 as a drug target also has the potential to provide valuable insights into the underlying mechanisms of many diseases. The regulation of the histone acetylation pathway is a complex process that involves the recruitment of multiple enzymes to the chromatin complex.MYST1 is the only enzyme that adds the acetyl groups to the histones, which allows it to play a critical role in the regulation of gene expression and the maintenance of chromosomal stability.

Understanding the function of MYST1 and its role in the regulation of the histone acetylation pathway is an important step in the development of new drugs that can treat a variety of diseases.MYST1 is a potential drug target that has the potential to treat a variety of diseases. Further research is needed to understand its function and develop new drugs that can modulate its activity.

Protein Name: Lysine Acetyltransferase 8

Functions: Histone acetyltransferase which may be involved in transcriptional activation (PubMed:12397079, PubMed:22020126). May influence the function of ATM (PubMed:15923642). As part of the MSL complex it is involved in acetylation of nucleosomal histone H4 producing specifically H4K16ac (PubMed:16227571, PubMed:16543150, PubMed:21217699, PubMed:22547026, PubMed:22020126). As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues (PubMed:20018852, PubMed:22547026). That activity is less specific than the one of the MSL complex (PubMed:20018852, PubMed:22547026). Can also acetylate TP53/p53 at 'Lys-120'

The "KAT8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KAT8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets